Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.

por Lissoni, P., Barni, S., Rescaldani, R., Rovelli, F., Tancini, G.
Publicado 1989

Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.

por Lissoni, P., Tancini, G., Rovelli, F., Cattaneo, G., Archili, C., Barni, S.
Publicado 1990

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.

por Lissoni, P., Barni, S., Meregalli, S., Fossati, V., Cazzaniga, M., Esposti, D., Tancini, G.
Publicado 1995

Evidence for altered opioid activity in patients with cancer.

por Lissoni, P., Barni, S., Paolorossi, F., Crispino, S., Rovelli, F., Ferri, L., Delitala, G., Tancini, G.
Publicado 1987

Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.

por Lissoni, P., Brivio, F., Pittalis, S., Perego, M. S., Ardizzoia, A., Mauri, O., Barni, S., Crispino, S., Tancini, G.
Publicado 1991

A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.

por Lissoni, P., Paolorossi, F., Tancini, G., Ardizzoia, A., Barni, S., Brivio, F., Maestroni, G. J., Chilelli, M.
Publicado 1996

Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.

por Lissoni, P., Barni, S., Tancini, G., Ardizzoia, A., Rovelli, F., Cazzaniga, M., Brivio, F., Piperno, A., Aldeghi, R., Fossati, D.
Publicado 1993

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and me...

por Lissoni, P., Barni, S., Tancini, G., Ardizzoia, A., Ricci, G., Aldeghi, R., Brivio, F., Tisi, E., Rovelli, F., Rescaldani, R.
Publicado 1994

Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.

por Lissoni, P., Tisi, E., Barni, S., Ardizzoia, A., Rovelli, F., Rescaldani, R., Ballabio, D., Benenti, C., Angeli, M., Tancini, G.
Publicado 1992